BioCentury | Jun 9, 2014
Analyst Picks & Changes

Analyst picks & changes

...and R&D of small molecules. Skorney said Theravance Biopharma inherited a diversified pipeline and that GSK961081...
BioCentury | May 20, 2013
Finance

Liquidity preference

...in the deal are vilanterol monotherapy, which is in Phase III testing for COPD; and GSK961081...
...as royalties of 10-20% on the first $3.5 billion of annual global net sales of GSK961081...
BioCentury | May 20, 2013
Company News

Elan, Theravance, GlaxoSmithKline deal

...EU; Anoro Ellipta umeclidinium bromide/vilanterol, which is under review in Japan, Europe and the U.S.; GSK961081...
...as royalties of 10-20% on the first $3.5 billion of annual global net sales of GSK961081...
...a long-acting muscarinic antagonist (LAMA) and vilanterol, both administered with the dry powder Ellipta inhaler. GSK961081...
BioCentury | May 14, 2013
Top Story

Elan paying Theravance for respiratory royalties

...Anoro Ellipta umeclidinium bromide/vilanterol, which is under review in Japan, Europe and in the U.S.; GSK961081...
...as royalties of 10-20% on the first $3.5 billion of annual global net sales of GSK961081...
...a long-acting muscarinic antagonist (LAMA) and vilanterol, both administered with the dry powder Ellipta inhaler. GSK961081...
BioCentury | Apr 29, 2013
Company News

Theravance infectious, gastrointestinal, pulmonary news

...for ADHD and fibromyalgia. The company will also develop two COPD programs partnered with GSK: GSK961081...
BioCentury | Apr 26, 2013
Company News

Theravance splitting up

...for ADHD and fibromyalgia. The company will also develop two COPD programs partnered with GSK: GSK961081...
BioCentury | May 28, 2012
Clinical News

GSK961081: Phase IIb data

...IIb trial in 436 patients with moderate to severe COPD showed that all doses of GSK961081...
...to day 29 vs. placebo (p<=0.001 for all). Specifically, once-daily 100, 400 and 800 µg GSK961081...
...San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK961081 ( 961081 ) (formerly TD-5959...
BioCentury | Mar 14, 2011
Regulation

Chronically Obstructed

...partners could file for approval on the monotherapies if they choose. GSK also is developing GSK961081...
...PT003 (formoterol/glycopyrrolate) Ph IIb (data in 2012) Theravance Inc. (NASDAQ:THRX)/GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) GSK961081 (formerly TD-5959...
BioCentury | Jan 10, 2011
Clinical News

GSK961081: Phase IIb started

...100, 400 or 800 µg doses or twice-daily 100, 200 or 400 µg doses of GSK961081...
...Inc. (NASDAQ:THRX), South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK961081 (formerly TD-5959...
BioCentury | Jul 21, 2008
Clinical News

GSK961081: Phase II data

...FEV1 by 103 mL vs. placebo (p=0.009). Compared with the active controls, both doses of GSK961081...
...maximum bronchodilation, although the study was not powered to compare GSK961081 vs. salmeterol plus tiotropium. GSK961081...
...Inc. (NASDAQ:THRX), South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: GSK961081 (formerly TD-5959...
Items per page:
1 - 10 of 17